# PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

> **NCT02787837** · — · UNKNOWN · sponsor: **Centro Nacional de Investigaciones Oncologicas CARLOS III** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Prostate Cancer
- Abiraterone ACetate

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02787837
- **Lead sponsor:** Centro Nacional de Investigaciones Oncologicas CARLOS III
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2018-04
- **Final completion:** 2020-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02787837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02787837, "PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02787837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*